Синдром LEOPARD

Синдром LEOPARD с множественными лентигами (кардиомиопатический лентигиноз) – редкое генетически детерминированное заболевание с аутосомно-доминантным типом наследования. Распространенность данного синдрома неизвестна. Одним из патогномоничных клинических проявлений синдрома служит наличие множественных лентигинозных пигментных пятен по всему телу. Наиболее частое кардиальное проявление (около 80 %) – гипертрофия миокарда. Нами представлен редкий клинический случай диагностики синдрома LEOPARD с множественными лентигами у пациентки в возрасте 32 лет с ведущими проявлениями в виде выраженных морфофункциональных изменений, гипертрофии миокарда и нарушений ритма сердца.

1. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2011;58(25):e212–60. DOI: 10.1016/j.jacc.2011.06.011

2. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal. 2014;35(39):2733–79. DOI: 10.1093/eurheartj/ehu284

3. Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2019;73(15):1978–86. DOI: 10.1016/j.jacc.2019.01.061

4. Sabater-Molina M, Pérez-Sánchez I, Hernández del Rincón JP, Gimeno JR. Genetics of hypertrophic cardiomyopathy: A review of current state. Clinical Genetics. 2018;93(1):3–14. DOI: 10.1111/cge.13027

5. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, Prognostic, and Therapeutic Implications of Genetic Testing for Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2009;54(3):201–11. DOI: 10.1016/j.jacc.2009.02.075

6. Seidman JG, Seidman C. The Genetic Basis for Cardiomyopathy. Cell. 2001;104(4):557–67. DOI: 10.1016/S0092-8674(01)00242-2

7. Lopes LR, Zekavati A, Syrris P, Hubank M, Giambartolomei C, Dalageorgou C et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. Journal of Medical Genetics. 2013;50(4):228–39. DOI: 10.1136/jmedgenet-2012-101270

8. Watkins H, Ashrafian H, Redwood C. Inherited Cardiomyopathies. New England Journal of Medicine. 2011;364(17):1643–56. DOI: 10.1056/NEJMra0902923

9. Coats CJ, Elliott PM. Genetic biomarkers in hypertrophic cardiomyopathy. Biomarkers in Medicine. 2013;7(4):505–16. DOI: 10.2217/bmm.13.79

10. Scaglia F. Clinical Spectrum, Morbidity, and Mortality in 113 Pediatric Patients With Mitochondrial Disease. Pediatrics. 2004;114(4):925–31. DOI: 10.1542/peds.2004-0718

11. Monserrat L, Gimeno-Blanes JR, Marín F, Hermida-Prieto M, García-Honrubia A, Pérez I et al. Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2007;50(25):2399–403. DOI: 10.1016/j.jacc.2007.06.062

12. Yang Z, McMahon CJ, Smith LR, Bersola J, Adesina AM, Breinholt JP et al. Danon Disease as an Underrecognized Cause of Hypertrophic Cardiomyopathy in Children. Circulation. 2005;112(11):1612–7. DOI: 10.1161/CIRCULATIONAHA.105.546481

13. Wilkinson JD, Lowe AM, Salbert BA, Sleeper LA, Colan SD, Cox GF et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: A study from the Pediatric Cardiomyopathy Registry. American Heart Journal. 2012;164(3):442–8. DOI: 10.1016/j.ahj.2012.04.018

14. Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet Journal of Rare Diseases. 2008;3(1):13. DOI: 10.1186/1750-1172-3-13

15. Falk RH. Diagnosis and Management of the Cardiac Amyloidoses. Circulation. 2005;112(13):2047–60. DOI: 10.1161/CIRCULATIONAHA.104.489187

16. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal. 2013;34(7):520–8. DOI: 10.1093/eurheartj/ehs123

17. Rapezzi C, Arbustini E, Caforio ALP, Charron P, Gimeno-Blanes J, Helio T et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2013;34(19):1448–58. DOI: 10.1093/eurheartj/ehs397

18. Gorlin RJ, Anderson RC, Blaw M. Multiple Lentigenes Syndrome. American Journal of Diseases of Children. 1969;117(6):652–62. DOI: 10.1001/archpedi.1969.02100030654006

19. Tajan M, Paccoud R, Branka S, Edouard T, Yart A. The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway. Endocrine Reviews. 2018;39(5):676–700. DOI: 10.1210/er.2017-00232

20. Rauen KA. The RASopathies. Annual Review of Genomics and Human Genetics. 2013;14(1):355–69. DOI: 10.1146/annurev-genom-091212-153523

21. Aoki Y, Niihori T, Inoue S, Matsubara Y. Recent advances in RASopathies. Journal of Human Genetics. 2016;61(1):33–9. DOI: 10.1038/jhg.2015.114

22. Martínez-Quintana E, Rodríguez-González F. LEOPARD Syndrome: Clinical Features and Gene Mutations. Molecular Syndromology. 2012;3(4):145–57. DOI: 10.1159/000342251

23. Voron DA, Hatfield HH, Kalkhoff RK. Multiple lentigines syndrome. The American Journal of Medicine. 1976;60(3):447–56. DOI: 10.1016/0002-9343(76)90764-6

24. Rizun L.I., Voronоva T.S., Frolova Yu.V., Raskin V.V., Rumiantseva V.A., Zakliaz’minskaia E.V. et al. Progressive cardiomyopathy by the LEOPARD syndrome. Pirogov Russian Journal of Surgery. 2012;12:56–61. [Russian: Ризун Л.И., Воронова Т.С., Фролова Ю.В., Раскин В.В., Румянцева В.А., Заклязьминская Е.В. и др. Прогрессирующая гипертрофическая кардиомиопатия при синдроме LEOPARD. Хирургия. Журнал имени Н.И. Пирогова. 2012;12:56-61]

25. Golousenko I.Yu., Glebova L.I., Kuleshov A.N. LEOPARD syndrome, LAMB syndrome or disseminated lentigines? Consilium Medicum. Dermatology. 2017;1:48–50. [Russian: Голоусенко И.Ю., Глебова Л.И., Кулешов А.Н. Синдром LEOPARD, синдром LAMB или диссеминированный лентигиноз? Дерматология. Прилижение к журналу Consilium Medicum. 2017;1:48-50]

26. Sanaani A, Fuisz A. Cardiac Magnetic Resonance for Diagnosis and Risk Stratification. Cardiology Clinics. 2019;37(1):27–33. DOI: 10.1016/j.ccl.2018.08.002

27. Maron BJ, Maron MS. The Remarkable 50 Years of Imaging in HCM and How it Has Changed Diagnosis and Management. JACC: Cardiovascular Imaging. 2016;9(7):858–72. DOI: 10.1016/j.jcmg.2016.05.003

28. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Journal of the American College of Cardiology. 2018;72(14):1677–749. DOI: 10.1016/j.jacc.2017.10.053

29. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapez­zi C et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). European Heart Journal. 2014;35(30):2010–20. DOI: 10.1093/eurheartj/eht439

30. O’Mahony C, Akhtar MM, Anastasiou Z, Guttmann OP, Vriesendorp PA, Michels M et al. Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart. 2018;105(8):623–31. DOI: 10.1136/heartjnl-2018-313700

31. Wakabayashi Y, Yamazaki K, Narumi Y, Fuseya S, Horigome M, Wakui K et al. Implantable cardioverter defibrillator for progressive hypertrophic cardiomyopathy in a patient with LEOPARD syndrome and a novel PTPN11 mutation Gln510His. American Journal of Medical Genetics Part A. 2011;155(10):2529–33. DOI: 10.1002/ajmg.a.34194